Please use this identifier to cite or link to this item:
https://ir.swu.ac.th/jspui/handle/123456789/12655
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Makarasen A. | |
dc.contributor.author | Kuno M. | |
dc.contributor.author | Patnin S. | |
dc.contributor.author | Reukngam N. | |
dc.contributor.author | Khlaychan P. | |
dc.contributor.author | Deeyohe S. | |
dc.contributor.author | Intachote P. | |
dc.contributor.author | Saimanee B. | |
dc.contributor.author | Sengsai S. | |
dc.contributor.author | Boonsri P. | |
dc.contributor.author | Chaivisuthangkura A. | |
dc.contributor.author | Sirithana W. | |
dc.contributor.author | Techasakul S. | |
dc.contributor.author | Dr. | |
dc.date.accessioned | 2021-04-05T03:04:46Z | - |
dc.date.available | 2021-04-05T03:04:46Z | - |
dc.date.issued | 2019 | |
dc.identifier.issn | 21949379 | |
dc.identifier.other | 2-s2.0-85075814506 | |
dc.identifier.uri | https://ir.swu.ac.th/jspui/handle/123456789/12655 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85075814506&doi=10.1055%2fa-0968-1150&partnerID=40&md5=ff3b3822d05ec10d157aa7796904d722 | |
dc.description.abstract | In this study, amino-oxy-diarylquinolines were designed using structure-guided molecular hybridization strategy and fusing of the pharmacophore templates of nevirapine (NVP), efavirenz (EFV), etravirine (ETV, TMC125) and rilpivirine (RPV, TMC278). The anti-HIV-1 reverse transcriptase (RT) activity was evaluated using standard ELISA method, and the cytotoxic activity was performed using MTT and XTT assays. The primary bioassay results indicated that 2-amino-4-oxy-diarylquinolines possess moderate inhibitory properties against HIV-1 RT. Molecular docking results showed that 2-amino-4-oxy-diarylquinolines 8(a-d) interacted with the Lys101 and His235 residue though hydrogen bonding and interacted with Tyr318 residue though π-π stacking in HIV-1 RT. Furthermore, 8a and 8d were the most potent anti-HIV agents among the designed and synthesized compounds, and their inhibition rates were 34.0% and 39.7% at 1 μM concentration. Interestingly, 8a was highly cytotoxicity against MOLT-3 (acute lymphoblastic leukemia), with an IC 50 of 4.63±0.62 μg/mL, which was similar with that in EFV and TMC278 (IC 50 7.76±0.37 and 1.57±0.20 μg/ml, respectively). Therefore, these analogs of the synthesized compounds can serve as excellent bases for the development of new anti-HIV-1 agents in the near future. © 2019 Georg Thieme Verlag. All rights reserved. | |
dc.subject | 4 (2',6' dimethyl 4' cyanophenoxy) 2 (4" cyanophenyl)aminoquinoline | |
dc.subject | 4 (2',6' dimethyl 4' cyanophenoxy) 2 chloroquinoline | |
dc.subject | 4 (2',6' dimethyl 4' cyanophenoxy) 6 (4'' cyanophenyl)aminoquinoline | |
dc.subject | 4 (2',6' dimethyl 4' cyanophenoxy) 6 nitroquinoline | |
dc.subject | 4 (2',6' dimethyl 4' formylphenoxy) 2 (4'' cyanophenyl)aminoquinoline | |
dc.subject | 4 (2',6' dimethyl 4' formylphenoxy) 2 chloroquinoline | |
dc.subject | 4 (2',6' dimethyl 4' formylphenoxy) 6 (4" cyanophenyl)aminoquinoline | |
dc.subject | 4 (2',6' dimethyl 4' formylphenoxy) 6 nitroquinoline | |
dc.subject | 4 (4' cyanophenoxy) 2 (4" cyanophenyl)aminoquinoline | |
dc.subject | 4 (4' cyanophenoxy) 2 chloroquinoline | |
dc.subject | 4 (4' cyanophenoxy) 6 (4'' cyanophenyl)aminoquinoline | |
dc.subject | 4 (4' cyanophenoxy) 6 nitroquinoline | |
dc.subject | 4 (4' formylphenoxy) 2 (4" cyanophenyl)aminoquinoline | |
dc.subject | 4 (4' formylphenoxy) 2 chloroquinoline | |
dc.subject | 4 (4' formylphenoxy) 6 (4'' cyanophenyl)aminoquinoline | |
dc.subject | 4 (4' formylphenoxy) 6 nitroquinoline | |
dc.subject | anti human immunodeficiency virus agent | |
dc.subject | antileukemic agent | |
dc.subject | doxorubicin | |
dc.subject | efavirenz | |
dc.subject | etoposide | |
dc.subject | etravirine | |
dc.subject | nevirapine | |
dc.subject | nonnucleoside reverse transcriptase inhibitor | |
dc.subject | quinoline derivative | |
dc.subject | rilpivirine | |
dc.subject | unclassified drug | |
dc.subject | anti human immunodeficiency virus agent | |
dc.subject | benzoxazine derivative | |
dc.subject | efavirenz | |
dc.subject | etravirine | |
dc.subject | nevirapine | |
dc.subject | pyridazine derivative | |
dc.subject | quinoline derivative | |
dc.subject | reverse transcriptase, Human immunodeficiency virus 1 | |
dc.subject | rilpivirine | |
dc.subject | RNA directed DNA polymerase | |
dc.subject | RNA directed DNA polymerase inhibitor | |
dc.subject | antileukemic activity | |
dc.subject | antiviral activity | |
dc.subject | Article | |
dc.subject | cell viability | |
dc.subject | comparative study | |
dc.subject | concentration response | |
dc.subject | controlled study | |
dc.subject | cytotoxicity | |
dc.subject | drug conformation | |
dc.subject | drug cytotoxicity | |
dc.subject | drug design | |
dc.subject | drug potency | |
dc.subject | drug protein binding | |
dc.subject | drug structure | |
dc.subject | drug synthesis | |
dc.subject | enzyme inhibition | |
dc.subject | enzyme linked immunosorbent assay | |
dc.subject | human | |
dc.subject | human cell | |
dc.subject | Human immunodeficiency virus 1 | |
dc.subject | hydrogen bond | |
dc.subject | IC50 | |
dc.subject | molecular docking | |
dc.subject | molecular hybridization | |
dc.subject | MOLT-3 cell line | |
dc.subject | MRC-5 cell line | |
dc.subject | MTT assay | |
dc.subject | pharmacophore | |
dc.subject | structure activity relation | |
dc.subject | XTT assay | |
dc.subject | chemistry | |
dc.subject | drug effect | |
dc.subject | Human immunodeficiency virus 1 | |
dc.subject | Human immunodeficiency virus infection | |
dc.subject | metabolism | |
dc.subject | molecular docking | |
dc.subject | tumor cell line | |
dc.subject | Anti-HIV Agents | |
dc.subject | Benzoxazines | |
dc.subject | Cell Line, Tumor | |
dc.subject | Diarylquinolines | |
dc.subject | HIV Infections | |
dc.subject | HIV Reverse Transcriptase | |
dc.subject | HIV-1 | |
dc.subject | Humans | |
dc.subject | Molecular Docking Simulation | |
dc.subject | Nevirapine | |
dc.subject | Pyridazines | |
dc.subject | Reverse Transcriptase Inhibitors | |
dc.subject | Rilpivirine | |
dc.title | Molecular Docking Studies and Synthesis of Amino-oxy-diarylquinoline Derivatives as Potent Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors | |
dc.type | Article | |
dc.rights.holder | Scopus | |
dc.identifier.bibliograpycitation | Drug Research. Vol 69, No.12 (2019), p.671-682 | |
dc.identifier.doi | 10.1055/a-0968-1150 | |
Appears in Collections: | Scopus 1983-2021 |
Files in This Item:
There are no files associated with this item.
Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.